Indication intelligence, analysis and sector perception

Dear Reader

February 16, 2014 4:07pm

Our subscription service starts soon!

It’s been months since we launched our news portal with even newer updates and we hope able to follow what matters in our regenerative medicine, stem cell and cell therapy universe.

Starting today, readers will notice some changes to the layout of the website. We have altered the look, feel and navigation at the top of the page to make it easier to find content relevant to the sector. The front page contains the same articles, video and information you are used to reading.

Trying to forge a deeper relationship with web users; RMi will experiment with a greater deal of personalization, using the pattern of a reader's previous visits to suggest what else he or she might be interested in. Finding the right mixture in online media between what every reader sees and what is most relevant is the important next step in establishing the nature of a relationship with our reader.

On the front page, you should also notice more features targeted at our large and growing audience in the region. And in the coming months, we'll be introducing more new ideas to add to the depth and range of our coverage.

Bundled into our RMi portal is our recently enhanced pre-open market primer with mid-day, closing bell opinion pieces and news alerts give you not just information but, interpreted analysis minute by minute. “Research Notes” delivers insight and pricing synthesis from the regenerative medicine and cell therapy investor universe.

The subscription model allows us to go deep and long on the more technical aspects of the RegMed science, research and finance worlds that dominate so much of the cell therapy’s universe. We provide conviction-based insight that’s tailored to help investors better manage risk. It also underwrites a broader mission of keeping investors up to date on the breaking news with a robust site that the subscription services help to make possible.

If you’ve found our services as useful as we’ve sought to make them, please consider contacting Henry at hwm@scimitarequity.com or on the phone at (617) 559.1080 to talk about how we can tailor a package to you or your organization’s information needs and budget before March 1.

Thanks,
Henry

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.